TB-500 Satisfaction Trends Over Time: What Real Users Report

HealthRX.com

No measured satisfaction trend exists for TB-500

Print or save as PDF

See the public record for TB-500

  • Compound / Synthetic 7-amino-acid fragment (residues 17 to 23) of thymosin beta-4 [1]
  • Closest human report / 75% of the 4 knee-pain patients given BPC-157 plus thymosin beta-4 reported significant improvement; the thymosin beta-4 form was not specified [2]
  • FDA adverse-event reports naming TB-500 / None through March 26, 2025 [1]
  • FDA compounding lists / On none of the three pharmacy-list categories or the outsourcing-facility list [3][4][5]
  • Sports status / Prohibited at all times, WADA S2.3 [6]

Is there any measured satisfaction trend?

A trend needs the same measure taken more than once in a defined group. We found no such repeated measurement for TB-500. What has changed recently is the regulatory record, not the clinical one [1][7][8].

What human reports exist

The closest thing to a user report in the published record is a 2021 retrospective chart review by Lee and Padgett at one Florida clinic. Of 16 patients reached by phone after intra-articular peptide injections, 12 received BPC-157 alone and 4 received BPC-157 plus thymosin beta-4; 75% of the 4 reported significant improvement, against 11 of 12 on BPC-157 alone. There was no control group, no validated tool, and patients were recalling their results. It was not a TB-500 satisfaction study, and the form of thymosin beta-4 used was not specified [2].

FDA's adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and its food and supplement complaint system retrieved two cases about a blended TB-500 and BPC-157 product with no safety assessment attached; FDA found no published case reports [1]. Its BPC-157 review describes a 40-year-old woman who injected a research-purpose BPC-157 plus TB-500 (5 mg/5 mg) product subcutaneously twice daily and developed widespread skin hyperpigmentation and gum darkening within a week, which recurred when she retried it. Because the product held two peptides, FDA said it cannot tell whether either one caused it [9].

Trials of full-length thymosin beta-4, a different molecule, do not fill the gap. A phase 1 study enrolled 54 healthy volunteers in single-dose cohorts receiving intravenous recombinant human thymosin beta-4 or placebo at 0.05 to 25 microgram/kg; adverse events were mild to moderate, with no serious ones [10].

What people on Reddit report

Two accounts from one early-use thread on a blended peptide product, covering side effects and how the product was sourced and dosed.

Slushfund_Underwritr · bpc_157

Sleep is sabotaged. Especially REM. Averaging 10-15 points lower on my sleep score consistently due to restlessness and poor REM.

Reports poorer sleep, especially dream sleep, on the same mix, alongside some pain relief and better flexibility.

Read the source discussion

Slushfund_Underwritr · bpc_157

5 on 2 off was recommended by the clinic I get it at. Just going with their recommendation. The bottle says TB-500.

Says the clinic chose the on-off schedule, the vial is labeled with the TB name, and they plan to separate the compounds next time.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Why online reports cannot be read as a trend

FDA found several salts and derivatives, including different active moieties, sold under the TB-500 name, and found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1]. The material is sold as research-use injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157 [1]. Online posts about products sold under that name may not describe the same substance.

What the regulatory record shows

  • TB-500 is not FDA-approved, and it appears in none of the three categories on FDA's state-licensed pharmacy list or on its outsourcing-facility list [1][3][4][5].
  • FDA staff proposed in July 2026 that neither the free base nor the acetate be added to the bulks list, citing no human data, poor characterization and immunogenicity risk [1]. The Pharmacy Compounding Advisory Committee reviewed TB-500 on July 23, 2026; advisory committee recommendations are non-binding [7].
  • An HHS draft policy filed October 28, 2026 says HHS does not intend enforcement action against certain licensed pharmacies and physicians compounding TB-500 acetate for injection if conditions are met. It establishes no rights and is not an approval [8][11].
  • WADA names thymosin-beta4 and its derivatives, including TB-500, in S2.3: prohibited at all times, in and out of competition [6][12].
  • FDA's stated concern for injectable TB-500 is immunogenicity, potentially amplified by peptide aggregation and impurities; it found no nonclinical toxicity studies and no human pharmacokinetic data by any route [1].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, what does a satisfaction trend require?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Do Reddit posts and review-site ratings count as evidence?
They are individual anecdotes, not measurements. Online ratings may leave out product identity, dose or the condition being discussed. FDA also found different salts and derivatives sold under the TB-500 name [1].
Is TB-500 approved or compoundable?
It is not FDA-approved and appears in none of the three categories on FDA's state-licensed pharmacy list or on its outsourcing-facility list [1][3][4][5]. The October 2026 HHS statement of intended enforcement discretion toward TB-500 acetate is a draft, is not binding and is not an approval [8][11].
What side effects are documented?
FDA retrieved no TB-500 reports in its adverse-event database through March 26, 2025 and found no published case reports [1]. Its stated concern for injectable TB-500 is immunogenicity. It also describes one hyperpigmentation case with a blended BPC-157 plus TB-500 product, where it could not attribute the reaction to either peptide [1][9].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

How long should I be on TB-500?

No duration guidance is given. No repeated satisfaction measurements over time exist for TB-500, and there is no human data on TB-500 itself, so how long use affects results is not established. The only human report is a 2021 chart review of 16 patients, with no control group and no validated tool.

Is TB500 better than BPC-157?

No comparison of TB-500 with BPC-157 for effectiveness exists. The closest human data involve BPC-157: in a 2021 retrospective review, 11 of 12 patients on BPC-157 alone reported significant improvement. That review had no control group and was not a TB-500 satisfaction study.

Is TB-500 worth it for daily maintenance?

Not established. There is no human data on TB-500 itself, no human pharmacokinetic data by any route, and no measured satisfaction trend over time. TB-500 is not FDA-approved, and FDA's stated concern for injectable TB-500 is immunogenicity.

Show all 13 referencesHide references
  1. U.S. Food and Drug Administration.
  2. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021.
  3. U.S. Food and Drug Administration.
  4. U.S. Food and Drug Administration.
  5. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding. Bulk Drug Substances Used in Compounding | FDA
  6. World Anti-Doping Agency.
  7. U.S. Food and Drug Administration.
  8. Official web page.
  9. U.S. Food and Drug Administration.
  10. Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
  11. Official web page.
  12. World Anti-Doping Agency.
  13. Reddit participants. Entering into week 3 of TB-500/BPC-157 (r/bpc_157). Accessed 2026-11-11.
Evidence overview for TB-500 Satisfaction Trends Over Time: What Real Users Report